Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China

References

• Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53(10):2623–2632.
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47(8):1360–1369.
   PubMed Web of Science ®Google Scholar
• Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (Clinical Research Ed). 2004;328(7446):983.
   PubMed Web of Science ®Google Scholar
• Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–959.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Romagnoli D, et al. The independent predictors of NASH and its individual histological features. Insulin resistance, serum uric acid, metabolic syndrome, ALT and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res off J Japan Soc. 2016;56(11):1074–1087.
   Google Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–944.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Romagnoli D, et al. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Adv Ther. 2016;33(3):291–319.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Reviews Dis Primers. 2015;1:15080.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol Ofl Clinl Pract J Am Gastroenterol Assoc. 2015;13(4):643-54.e1-9;quiz e39-40.
   Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273.
   PubMed Web of Science ®Google Scholar
• Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859–871.
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol. 1999;116(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–743.
   PubMed Web of Science ®Google Scholar
• Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94(10):3010–3014.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101(1):76–82.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterol. 2004;126(2):460–468.
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533–539.
   PubMed Web of Science ®Google Scholar
• Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res off J Japan Soc. 2013;43(1):51–64.
   PubMed Web of Science ®Google Scholar
• de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22(5):756–761.
   PubMed Web of Science ®Google Scholar
• Trombetta M, Spiazzi G, Zoppini G, et al. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22(Suppl 2):24–27.
   PubMed Web of Science ®Google Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960–967.
   PubMed Web of Science ®Google Scholar
• West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM Mon J Assoc Physicians. 2006;99(12):871–876.
   PubMed Web of Science ®Google Scholar
• Meybodi MA, Afkhami-Ardekani M, Rashidi M. Prevalence of abnormal serum alanine aminotransferase levels in type 2 diabetic patients in Iran. Pak J Biol Sci. 2008;11(18):2274–2277.
   PubMedGoogle Scholar
• Belkacemi L, Belalia M. Cross-sectional pilot study about the liver enzymes profile in type 2 diabetic patients from an Algerian west region: wilaya of Mostaganem. Diabetes Metab Syndr. 2016;10(1 suppl 1):s147–50.
   PubMedGoogle Scholar
• Jiamjarasrangsi W, Lertmaharit S, Sangwatanaroj S, et al. Type 2 diabetes, impaired fasting glucose, and their association with increased hepatic enzyme levels among the employees in a university hospital in Thailand. J Med Assoc Thai. 2009;92(7):961–968.
   PubMedGoogle Scholar
• Leeds JS, Forman EM, Morley S, et al. Abnormal liver function tests in patients with type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med. 2009;26(12):1235–1241.
   PubMed Web of Science ®Google Scholar
• Morling JR, Strachan MW, Hayes PC, et al. Prevalence of abnormal plasma liver enzymes in older people with type 2 diabetes. Diabet Med. 2012;29(4):488–491.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Petrie J, Littler W, et al. An outline of the revised British hypertension society protocol for the evaluation of blood pressure measuring devices. J Hypertens. 1993;11(6):677–679.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertens. 2003;42(6):1206–1252.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee. Hypertension control. Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1996;862:1–83.
   PubMedGoogle Scholar
• WHO/FAO Expert Committee. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 2003;916:i-viii, 1-149, backcover.
   PubMed Web of Science ®Google Scholar
• Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev. 2010;23(2):247–269.
   PubMed Web of Science ®Google Scholar
• Chen ZW, Chen LY, Dai HL, et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9(8):616–622.
   PubMed Web of Science ®Google Scholar
• Chen S, Guo X, Zhang X, et al. Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study. BMC Cardiovasc Disord. 2015;15:65.
   PubMed Web of Science ®Google Scholar
• Chen S, Guo X, Yu S, et al. Metabolic syndrome and serum liver enzymes in the general chinese population. Int J Environ Res Public Health. 2016;13:2.
   Web of Science ®Google Scholar
• Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109(7):588–590.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815–821.
   PubMed Web of Science ®Google Scholar
• Forlani G, Di Bonito P, Mannucci E, et al. Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest. 2008;31(2):146–152.
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Russell AJ, Prins JB, et al. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease? Diabetes Res Clin Pract. 2008;80(1):e10–2.
   Google Scholar
• Hermos JA, Cohen SA, Hall R, et al. Association of elevated alanine aminotransferase with BMI and diabetes in older veteran outpatients. Diabetes Res Clin Pract. 2008;80(1):153–158.
   PubMed Web of Science ®Google Scholar
• Judi L, Toukan A, Khader Y, et al. Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. Ann Saudi Med. 2010;30(1):25–32.
   PubMed Web of Science ®Google Scholar
• Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000;46(12):2027–2049.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006.
   PubMedGoogle Scholar
• Siest G, Schiele F, Galteau MM, et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem. 1975;21(8):1077–1087.
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatol. 1999;30(6):1356–1362.
   PubMed Web of Science ®Google Scholar
• Sherman KE. Alanine aminotransferase in clinical practice. Rev Arch Internal Med. 1991;151(2):260–265.
   PubMedGoogle Scholar